Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Blackstone Inc (BX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Blackstone Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Blackstone Inc trades at $118.65 (market cap $147.67B). The key difference: Blackstone Inc is far larger — about 32.9× ACADIA Pharmaceuticals Inc.'s market cap, and Blackstone Inc pays a 4.11% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BX | |
|---|---|---|
Market Cap | $4.49B | $147.67B |
Sector | Health | Financials |
52-Week High | $28.06 | $188.68 |
52-Week Low | $20.06 | $102.12 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BX trades at $120.88, down 1.51% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41B in 2025, with a net income margin of 24.27% and robust ROE of 37.36%. Recent news highlights strategic moves in energy transition, AI data centers, and credit markets, including a $30B Japan AI investment plan reported by Reuters on June 23, 2026.
Outlook remains positive with a consensus price target of $150.78, implying 25% upside, supported by 62% analyst buy ratings. Risks include execution of large investments and market volatility, but fundamentals and institutional sentiment favor long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
